文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

季铵盐-18 阳离子油包水纳米乳用于眼部局部给药的优势。

Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery.

出版信息

J Pharm Pharmacol. 2014 Apr;66(4):531-41. doi: 10.1111/jphp.12075.


DOI:10.1111/jphp.12075
PMID:24001405
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4283994/
Abstract

OBJECTIVES: Topical ocular administration is the most convenient route of administration of drugs for the treatment of eye diseases. However, the bioavailability of drugs following eye instillations of eye drops is very low. Over the past 20 years, extensive efforts have been put into research to improve drug bioavailability without compromising treatment compliance and patients' quality of life. KEY FINDINGS: One of the most efficient ways to improve drug bioavailability is to increase the precorneal residence time of the eye drop formulations. As a result, new eye drops, with bioadhesive properties, have been developed based on the cationic oil-in-water (o/w) nanoemulsion technology. These low viscosity eye drop nanoemulsions have improved precorneal residence time through the electrostatic interactions between the positively charged oil nanodroplets and the negatively charged ocular surface epithelium. SUMMARY: This review is the first to present the benefits of this new strategy used to improve ocular drug bioavailability. The roles of the cationic agent in the stabilization of a safe cationic o/w nanoemulsion have been discussed, as well as the unexpected benefits of the cationic o/w nanoemulsion for the protection and restoration of a healthy tear film and corneal epithelium.

摘要

目的:眼部局部给药是治疗眼部疾病的最方便的药物给药途径。然而,滴眼剂滴入眼睛后药物的生物利用度非常低。在过去的 20 年中,人们进行了广泛的研究,试图在不影响治疗顺应性和患者生活质量的情况下提高药物的生物利用度。

主要发现:提高药物生物利用度最有效的方法之一是增加滴眼剂配方在眼前部的停留时间。因此,基于阳离子油包水(o/w)纳米乳液技术,开发了具有生物黏附特性的新型滴眼剂。这些低粘度的滴眼纳米乳液通过带正电荷的油纳米液滴与带负电荷的眼表面上皮之间的静电相互作用,提高了在眼前部的停留时间。

总结:这是第一篇介绍这种用于提高眼部药物生物利用度的新策略的益处的综述。本文讨论了阳离子剂在稳定安全的阳离子 o/w 纳米乳液中的作用,以及阳离子 o/w 纳米乳液在保护和恢复健康的泪膜和角膜上皮方面的意外益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/eae0689ccb0c/jphp0066-0531-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/005e1e1ac31f/jphp0066-0531-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/fafbada84522/jphp0066-0531-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/380e4544be1d/jphp0066-0531-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/2959991f3069/jphp0066-0531-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/09bb4b578130/jphp0066-0531-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/6d0ef6dad57e/jphp0066-0531-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/eae0689ccb0c/jphp0066-0531-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/005e1e1ac31f/jphp0066-0531-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/fafbada84522/jphp0066-0531-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/380e4544be1d/jphp0066-0531-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/2959991f3069/jphp0066-0531-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/09bb4b578130/jphp0066-0531-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/6d0ef6dad57e/jphp0066-0531-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e03/4283994/eae0689ccb0c/jphp0066-0531-f7.jpg

相似文献

[1]
Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery.

J Pharm Pharmacol. 2014-4

[2]
In vitro evaluation of stearylamine cationic nanoemulsions for improved ocular drug delivery.

Acta Pharm. 2019-12-1

[3]
Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability.

Drug Deliv. 2016-11

[4]
Cationic nanoemulsions with prolonged retention time as promising carriers for ophthalmic delivery of tacrolimus.

Eur J Pharm Sci. 2020-1-17

[5]
The influence of cationic lipid type on in-vitro release kinetic profiles of antisense oligonucleotide from cationic nanoemulsions.

Eur J Pharm Biopharm. 2008-9

[6]
Ocular preparations: the formulation approach.

Drug Dev Ind Pharm. 2002-5

[7]
Safety and Tolerability of Overdosed Artificial Tears by Abraded Rabbit Corneas.

J Ocul Pharmacol Ther. 2018-10-12

[8]
Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.

AAPS PharmSciTech. 2021-3-14

[9]
Novel Ocular Drug Delivery Systems: An Update on Microemulsions.

J Ocul Pharmacol Ther. 2020

[10]
In vitro and In vivo Studies on a Novel Bioadhesive Colloidal System: Cationic Liposomes of Ibuprofen.

AAPS PharmSciTech. 2017-10-2

引用本文的文献

[1]
Nanoemulsions Based Therapeutic Strategies: Enhancing Targeted Drug Delivery against Breast Cancer Cells.

Int J Nanomedicine. 2025-5-14

[2]
The evolving role of ciclosporin in the management of vernal keratoconjunctivitis.

Front Ophthalmol (Lausanne). 2025-4-25

[3]
Effectiveness of 0.1% Cyclosporine a Cationic Emulsion for Treating Dry Eye Disease After Cataract Surgery Analyzed Using a Placido Tear Film Analyzer.

Diagnostics (Basel). 2025-4-12

[4]
In Vitro Toxicity of Cetalkonium Chloride on Corneal Epithelial Cells.

Pharmaceutics. 2025-4-16

[5]
Nano-based drug delivery systems for the treatment of non-infectious uveitis.

Adv Ophthalmol Pract Res. 2024-11-12

[6]
A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension.

Eye (Lond). 2025-6

[7]
Recent Advances in Cationic Nanoemulsions for Drug Delivery: Preparation, Properties, and Applications.

Curr Pharm Des. 2025

[8]
Clinical efficacy of 0.1% cyclosporine A in dry eye patients with inadequate responses to 0.05% cyclosporine A: a switching, prospective, open-label, multicenter study.

BMC Ophthalmol. 2025-1-22

[9]
Simvastatin is delivered to the brain by high-strength intranasal cationic SMEDDS and nanoemulsions.

Drug Deliv Transl Res. 2025-1-2

[10]
Recent Advances in Nanotechnology for the Treatment of Dry Eye Disease.

Nanomaterials (Basel). 2024-4-12

本文引用的文献

[1]
Comparison of the Anti-Inflammatory Effects of Artificial Tears in a Rat Model of Corneal Scraping.

J Ocul Pharmacol Ther. 2016-3

[2]
Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits.

Cornea. 2013-3

[3]
In vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models.

Cornea. 2012-11

[4]
Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model.

Mol Vis. 2012

[5]
A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.

J Ocul Pharmacol Ther. 2012-6-6

[6]
Controlled and continuous release ocular drug delivery systems: pros and cons.

Curr Drug Deliv. 2012-7

[7]
Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.

J Drug Deliv. 2012

[8]
Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines.

Br J Ophthalmol. 2011-5-20

[9]
Ocular drug delivery - a look towards nanobioadhesives.

Expert Opin Drug Deliv. 2011-1

[10]
Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.

Adv Ther. 2010-10-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索